Mergers and innovation in the pharmaceutical industry

Journal of Health Economics

Volumn 32, Issue 1, 2013, Pages 106-113

  Comanor, William S ^a   Scherer, F M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Innovation; Pharmacuetical mergers

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT;

CORPORATE STRATEGY; INNOVATION; MERGER; PHARMACEUTICAL INDUSTRY; PRODUCTIVITY; RESEARCH AND DEVELOPMENT;

ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MERGERS AND ACQUISITIONS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRODUCTIVITY; TECHNOLOGY;

BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; EFFICIENCY; EFFICIENCY, ORGANIZATIONAL;

EID: 84872253177     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2012.09.006     Document Type: Article

References (30)

1. Abernathy W., Rosenbloom R. Parallel strategies in development projects. Management Science 1969, 18(June).
2. Baxter, J.P., 1947. Scientists Against Time (Little-Brown).
3. Cockburn I.M., Henderson R. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Journal of Health Economics 2001, 20:1033-1057.
4. Comanor W.S. The economics of research and development in the pharmaceutical industry. Pharmaceutical Innovation 2007, 54-72. Cambridge University Press. F. Sloan, C.R. Hsieh (Eds.).
5. Comanor W.S., Scherer F.M. Patent statistics as a measure of technical change. Journal of Political Economy 1969, 77(May/June):392-398.
6. DiMasi J., Grabowski H. The cost of biopharmaceutical R&D: is biotech different?. Managerial and Decision Economics 2007, 28:469-479.
7. DiMasi J.A., Paquette C. The economics of follow-on research and development. Pharmacoeconomics 2004, 22:1-14.
8. DiMasi J., Hansen R., Grabowski H. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003, 22:151-185.
9. Eli Lilly and Co., 2002. Annual report.
10. Grabowski H., Vernon J. A new look at the returns and risks to pharmaceutical R&D. Management Science 1990, 36(July):804-821.
11. Grabowski H., Vernon J., DiMasi J. Returns on research and development for 1990s new drug innovations. Pharmacoeconomics 2002, 20:11-29.
12. Hall B., Mairesse J., Mohnen P. Measuring the returns to R&D. Handbook of the Economics of Innovation 2010, North-Holland, Amsterdam, (Chapter 24). Hall, N. Rosenberg (Eds.).
13. Henderson R. Managing innovation in the information age. Harvard Business Review 1994, (January-February):100-105.
14. Hitch C.J., McKean R. The Economics of Defense in the Nuclear Age 1960, Harvard University Press, Cambridge, Mass.
15. Kirsner S. Venture firms with a twist. Boston Sunday Globe 2012, (June):G1.
16. LaMattina J.L. The impact of mergers on pharmaceutical R&D. Nature Reviews/Drug Discovery 2011, 10(August):559-560.
17. Lichtenberg F. Pharmaceutical innovation, mortality reduction, and economic growth. Measuring the Gains from Medical Research 2003, 74-109. University of Chicago Press, Chicago. K. Murphy, R. Topol (Eds.).
18. Mansfield E., et al. Social and private rates of return from industrial innovations. Quarterly Journal of Economics 1977, 91(May):221-240.
19. Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Reviews/Drug Discovery 2009, 8(December):959-968.
20. Nelson R.R. Uncertainty, learning, and the economics of parallel research and development. Review of Economics and Statistics 1961, 43(November):351-368.
21. Peck M.J., Scherer F.M. The Weapons Acquisition Process: An Economic Analysis 1962, Harvard Business School Division of Research, Boston.
22. Pisano G. Science Business: The Promise, the Future, and the Reality of Biotech 2006, Harvard Business School Press, Boston.
23. Preis, Z.M., 2005. The incentive theory of patents in action. Harvard Law School Doctoral Thesis. September (privately published).
24. Primack D. Why you should blame Wall Street for pharma's startup problem. Fortune 2011, (December):82.
25. Scherer F.M. Time-cost trade-offs in uncertain empirical research projects. Naval Research Logistics Quarterly 1966, 13(March):71-82. Reprinted in Innovation and Growth: Schumpeterian Perspectives (MIT Press: 1984), Chapter 2.
26. Scherer F.M. Industry Structure, Strategy, and Public Policy 1996, HarperCollins, New York.
27. Scherer, F.M., 2007, September. Parallel R&D paths revisited. John F. Kennedy School of Government working paper RWP07-049.
28. Scherer F.M. Pharmaceutical innovation. Handbook of the Economics of Innovation 2010, North-Holland, Amsterdam, (Chapter 12). B. Hall, N. Rosenberg (Eds.).
29. Scherer F.M. R&D costs and productivity in biopharmaceuticals, John F. Kennedy School of Government working paper RWP11-046. Encyclopedia of Health Economics 2013, Elsevier, Oxford. A. Culyer (Ed.).
30. Sobel D. Longitude 1995, Walker, New York.